Related Experiment Videos
EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression
1Department of Pathology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8118, St. Louis, MO 63110, USA.
Abstract:
The identification of EGR2 mutations in patients with neuropathies and the phenotype Egr2/Krox20(-/-) have demonstrated that the Egr2 transcription factor is critical for peripheral nerve myelination. However, the mechanism by which these mutations cause disease remains unclear, as most patients present with disease in the heterozygous state, whereas Egr2(+/-) mice are phenotypically normal. To understand the effect of aberrant Egr2 activity on Schwann cell gene expression, we performed microarray expression profiling to identify genes regulated by Egr2 in Schwann cells. These include genes encoding myelin proteins and enzymes required for synthesis of normal myelin lipids. Using these newly identified targets, we have shown that neuropathy-associated EGR2 mutants dominant-negatively inhibit wild-type Egr2-mediated expression of essential myelin genes to levels sufficiently low to result in the abnormal myelination observed in these patients.
Insights
Mutations in the EGR2 gene cause peripheral neuropathies by disrupting myelin production. Aberrant EGR2 mutants inhibit normal EGR2 function, leading to impaired myelination and nerve disease.
Area of Science:
- Molecular Biology
- Neuroscience
- Genetics
Background:
- The transcription factor EGR2 (Early Growth Response 2) is essential for peripheral nerve myelination.
- EGR2 mutations are linked to neuropathies, but the underlying mechanism, especially in heterozygous states, is not fully understood.
- Heterozygous Egr2(+/-) mice are phenotypically normal, contrasting with human patient presentations.
Purpose of the Study:
- To elucidate the mechanism by which EGR2 mutations cause peripheral neuropathies.
- To identify genes regulated by EGR2 in Schwann cells and understand the impact of aberrant EGR2 activity.
Main Methods:
- Microarray expression profiling was employed to identify genes directly regulated by EGR2 in Schwann cells.
- Analysis focused on identifying novel EGR2 target genes involved in myelination.
Main Results:
- Microarray analysis identified genes crucial for myelin protein synthesis and lipid metabolism as EGR2 targets.
- Neuropathy-associated EGR2 mutants were found to exert a dominant-negative effect on wild-type EGR2.
- This inhibition reduces the expression of essential myelin genes to levels causing abnormal myelination.
Conclusions:
- EGR2 mutations cause peripheral neuropathies through a dominant-negative mechanism, impairing Schwann cell function.
- Aberrant EGR2 activity disrupts the expression of critical myelin genes, leading to disease phenotypes.
- Understanding this mechanism provides insight into the pathogenesis of EGR2-associated neuropathies.